ReNeuron Group plc ReNeuron presents in vivo data at Cell 2023 (6891S)
08 Noviembre 2023 - 1:00AM
UK Regulatory
TIDMRENE
RNS Number : 6891S
ReNeuron Group plc
08 November 2023
ReNeuron Group plc
("ReNeuron" or "the Group")
ReNeuron presents in vivo data at Cell 2023
In vivo data highlights the specific tissue and cellular
targeting capabilities
of ReNeuron's stem cell derived exosome drug delivery platform,
CustomEX(TM)
ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell
derived exosome technologies, announces that Dr Samantha Thomas
will be presenting in vivo data exemplifying the cellular and
tissue targeting capabilities and highlighting the significant
advantages of ReNeuron's CustomEX(TM) drug delivery platform, at
Cell 2023 in London.
Key highlights from the presentation entitled Targeted Delivery
of Therapeutic Payloads Using Stem Cell derived Exosome
include:
-- Confirmation in vitro and in vivo that exosome targeting is
dependent on cell source and selection of a specific exosome
population results in the improved delivery of therapeutic payloads
when compared to a conventional HEK293 exosome approach.
-- A specific CustomEX(TM) exosome targets the lymph nodes
(immune system) proportionately more than other exosome types.
-- A specific CustomEX(TM) exosome selectively targets the tubules within the kidney.
-- A specific CustomEX(TM) exosome targets the lung following systemic administration.
-- Confirmation that therapeutic payloads can be successfully
delivered in vivo using the CustomEX(TM) platform following
systemic administration.
-- No evidence of immune response or toxicity with any of the
exosome candidates, opening up the possible use of CustomEX(TM) for
repeat administration unlike viral vectors.
These data highlight the significant improvement in targeting
and delivery of payloads that can be achieved through the careful
selection of specific exosomes from different cell sources.
ReNeuron's CustomEX(TM) platform, is a compelling platform that
offers this ability to select the exosome cell type for a partner's
need and the payload / target cell of their choice, while offering
a scalable and repeatable manufacturing process due to its patented
conditional immortalisation technology. This technology was enabled
through the Group's earlier work in producing GMP stem cells
approved by the FDA and MHRA for the clinic from which the Group's
exosomes are now produced.
The presentation from the conference will also be available on
the ReNeuron website after the event:
https://www.reneuron.com/investors/presentations/
CustomEX(TM) is a register trademark of ReNeuron Limited.
Enquiries:
ReNeuron www.reneuron.com/investors
Iain Ross, Executive Chairman Via Walbrook PR
John Hawkins, Chief Financial Officer
Allenby Capital Limited (Nominated
Adviser and Broker) +44 (0)20 3328 5656
James Reeve / George Payne /
Dan Dearden-Williams (Corporate Finance)
Stefano Aquilino (Sales & Corporate
Broking)
Walbrook PR (Media & Investor Relations) +44 (0)20 7933 8780 or reneuron@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7407
Paul McManus / Alice Woodings 804 654
About ReNeuron
ReNeuron has developed a proprietary stem cell-derived,
exosome-based, drug delivery platform with customisable cellular
targeting capabilities for the delivery of complex drug
modalities.
Through the generation of several unique and scalable exosome
producer cell lines, our CustomEX(TM) platform can be optimised for
specific tissues targets and payloads leading to improvements in
therapeutic outcome and a reduction in off-target effects. ReNeuron
offers a delivery mechanism for a variety of payloads such as
siRNA, mRNA, proteins, small molecules and genes. Through its
conditionally immortalised induced pluripotent stem cell (iPSC)
platform, the Group can make allogeneic tissue cells of choice and
has the potential to produce exosomes with tissue specific
targeting ability.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. For further information visit www.reneuron.com
This announcement contains forward-looking statements with
respect to the financial condition, results of operations and
business achievements/performance of ReNeuron and certain of the
plans and objectives of management of ReNeuron with respect
thereto. These statements may generally, but not always, be
identified by the use of words such as "should", "expects",
"estimates", "believes" or similar expressions. This announcement
also contains forward-looking statements attributed to certain
third parties relating to their estimates regarding the growth of
markets and demand for products. By their nature, forward-looking
statements involve risk and uncertainty because they reflect
ReNeuron's current expectations and assumptions as to future events
and circumstances that may not prove accurate. A number of factors
could cause ReNeuron's actual financial condition, results of
operations and business achievements/performance to differ
materially from the estimates made or implied in such
forward-looking statements and, accordingly, reliance should not be
placed on such statements.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCUBONRONUARAA
(END) Dow Jones Newswires
November 08, 2023 02:00 ET (07:00 GMT)
Reneuron (LSE:RENE)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Reneuron (LSE:RENE)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
